scholarly journals Evaluation of Ki67 Expression in Relation to Tumor Stage and Fuhrman Nuclear Grade of Renal Cell Carcinoma and MUC1 Expression in Clear Cell Renal Cell Carcinoma

2021 ◽  
Vol 10 (33) ◽  
pp. 2718-2722
Author(s):  
Sarumathy Ganesan ◽  
Prathiba Arumugam ◽  
Nithya Ilanchezhian ◽  
Saraswathi Manickam
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Labelling Index ◽  
Nuclear Grade ◽  
Muc1 Expression ◽  
Cell Renal Cell Carcinoma ◽  
Ki67 Expression ◽  
Clear Cell Rcc

BACKGROUND Renal cell carcinoma (RCC) is the most common malignant renal tumour in adults. Prognosis of RCC depends on various factors like tumour stage, nuclear grade and histological type. For planning adjuvant therapy, accurate prediction of prognosis is mandatory. In many studies, ki67 and MUC1 has shown to be of prognostic significance and immunohistochemical expression of these two markers plays an important role in determining the prognosis of RCC. The purpose of this study was to evaluate the Ki67 expression in histologically confirmed cases of RCC and MUC1 expression in clear cell renal cell carcinoma, and to correlate them with the stage and Fuhrman nuclear grade of the tumour, in order to determine their role as prognostic markers in RCC. METHODS This study was a retrospective study. A total of 50 specimens of renal cell carcinoma were studied. The specimens were total and partial nephrectomy done in the department of urology for a period of 3 years. Expression of Ki67 and MUC1 in RCC were studied by immunohistochemistry (IHC). Statistical analysis was performed and P value < 0.05 was considered significant. RESULTS Out of 50 RCC studied, Ki67 labelling index ≥ 15 % was found in 35 cases. For MUC1, immunoreactivity of more than 10 % of tumor cell was found in 28/34 of clear cell RCC. In this study, Ki67 labelling index showed statistically significant expression with the stage of tumor and the nuclear grade. MUC1 expression also showed significant correlation with nuclear grade and stage of clear cell RCC. CONCLUSIONS High Ki67 labelling index in renal cell carcinoma is seen to correlate with higher nuclear grade and stage of tumor. High level expression with circumferential staining pattern of MUC1 is seen in high grade tumours with increased risk of metastasis. So MUC1 and Ki67 can be considered as a marker of prognosis of RCC. KEY WORDS Renal Cell Carcinoma, Immunohistochemistry, Ki67, MUC1

Expression of theForkheadTranscription Factor FOXP1 is Associated with Tumor Grade and Ki67 Expression in Clear Cell Renal Cell Carcinoma

2011 ◽  
Vol 29 (2) ◽  
pp. 123-129 ◽  
Author(s):  
Marieta I. Toma ◽  
Thomas Weber ◽  
Matthias Meinhardt ◽  
Stefan Zastrow ◽  
Marc-Oliver Grimm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Tumor Grade ◽  
Cell Renal Cell Carcinoma ◽  
Ki67 Expression

Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 699-699
Author(s):  
Laurence Albiges ◽  
Damien Pouessel ◽  
Marie Beylot-Barry ◽  
Guido Bens ◽  
Diane Pannier ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prospective Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Type I ◽  
Cell Renal Cell Carcinoma ◽  
Duct Carcinoma ◽  
Clear Cell Rcc

699 Background: AcSe Nivolumab (N), is a non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in patients (pts) with specific rare cancers (NCT03012581). We report on the non-clear cell renal cell carcinoma (RCC) cohort. Methods: Primary endpoint was objective response rate (ORR) at 12 weeks according to RECIST1.1. All pts receives N at 240mg IV every 2 weeks. Secondary endpoints included progression free survival (PFS), overall survival (OS), best response, and safety. Results: Between 07/2017 and 02/2019, 50 pts have been enrolled across 13 institutions. Median age was 61.4 years old, 70% were male. ECOG PS was 0, 1, 2, in 29%, 63% and 8% of pts respectively. Histological types were papillary (pRCC) type 2 (41%), chromophobe (18%), pRCC type I (10%), pRCC unclassified (8%), collecting duct carcinoma (CDC) (8%), and others (including predominant sarcomatoid, renal medullary carcinoma, MITF associated RCC, unclassified RCC). N was used in first line in 16%, second line in 54% and third line or beyond in 30%. IMDC risk group was 14%, 70% and 16% for good, intermediate and poor risk respectively. With a median follow up of 10.4 months (mo), 42 pts had discontinued N. The 12 weeks-ORR was 6% (3 PR), with stable disease in 49% and PD in 44% of pts. The best ORR was 10%. Median PFS was 3.9 mo (IC95% [2.9; 8.3]). At time of analysis, 25 pts (50%) had died and 12-months OS rate was 47.7% (IC95% [33.5; 67.8]). Overall, 31 pts (62%) have presented at least one grade ≥ 3 AE. No new safety signal with N was reported. 12 weeks-ORR and best ORR according to distinct histology are presented in table 1. Pts with PR were 1pRCC type 2, 1pRCC type 1, 1 CDC, 1 MITF RCC and 1 unclassified. Conclusions: We report the first prospective study of N single agent in non-clear cell RCC. N demonstrates limited activity in a pretreated and heterogeneous non- clear cell RCC population. Interestingly 1/4 CDC developed PR while no response was noted in chromophobe RCC. Clinical trial information: NCT03012581. [Table: see text]

A novel preoperative inflammatory marker prognostic score in patients with clear cell and non-clear cell renal cell carcinoma.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 530-530
Author(s):  
Rishi Robert Sekar ◽  
Dattatraya Patil ◽  
Jeff Pearl ◽  
Yoram Baum ◽  
Omer Kucuk ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Medical Decision ◽  
Chi Square ◽  
Cell Renal Cell Carcinoma ◽  
Clear Cell Rcc ◽  
Chi Square Analysis

530 Background: Several inflammatory markers have been studied as potential biomarkers in clear cell renal cell carcinoma (RCC), however few reports have analyzed their prognostic value in aggregate and in non-clear cell histologies. We hypothesize that a combination of preoperative C-Reactive Protein (CRP), albumin, Erythrocyte Sedimentation Rate (ESR), corrected calcium, and AST/ALT ratio into a RCC Inflammatory Score (RISC) could serve as a rigorous prognostic indicator in patients with clear cell and non-clear cell RCC. Methods: Patients that underwent nephrectomy for localized RCC were queried from our nephrectomy database. The optimal threshold for individual biomarkers was determined using grid search methodology, receiver operating characteristic (ROC) analysis, and sensitivity-specificity trade-off analysis. The final score, RISC, was the sum of points accrued from each biomarker (Table). ROC and chi-square analysis was performed to compare the prognostic ability of RISC to SSIGN and UISS. Impact on overall survival was analyzed with multivariate logistic regression analysis. Results: 391 patients were included in the study. Area under the curve (AUC) for RISC, SSIGN, and UISS was 0.78, 0.78, and 0.81, respectively. Chi-square analysis of AUCs revealed no statistically significant difference between RISC, SSIGN, and UISS (p= 0.820, and p =0.317, respectively). On multivariate analysis, after adjusting for confounding variables, each unit increase in RISC was associated with a 32% increase in mortality (HR=1.32, 95%CI 1.17-1.49, p<0.001). Conclusions: RISC is an independent and significant predictor of overall survival in clear cell and non-clear cell RCC with accuracy at least as good as other established prognostic tools. Notably, RISC is composed of standardized preoperative laboratory markers, allowing crucial prognostic information to be integrated into medical decision making prior to surgery. [Table: see text]

Utility of the Apparent Diffusion Coefficient for Distinguishing Clear Cell Renal Cell Carcinoma of Low and High Nuclear Grade

2010 ◽  
Vol 195 (5) ◽  
pp. W344-W351 ◽  
Author(s):  
Andrew B. Rosenkrantz ◽  
Benjamin E. Niver ◽  
Erin F. Fitzgerald ◽  
James S. Babb ◽  
Hersh Chandarana ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Diffusion Coefficient ◽  
Apparent Diffusion Coefficient ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Nuclear Grade ◽  
Cell Renal Cell Carcinoma ◽  
High Nuclear Grade ◽  
Apparent Diffusion

Overexpression of IL-32 as a novel prognostic factor in patients with clear cell renal cell carcinoma after a nephrectomy.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 413-413
Author(s):  
Hyo Jin Lee ◽  
Hyun-Jung Lee ◽  
Zhe Long Liang ◽  
Jae-Sung Lim ◽  
Jin Man Kim
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Survival Rates ◽  
Staining Intensity ◽  
Nuclear Grade ◽  
Recurrence Rates ◽  
Cell Renal Cell Carcinoma

413 Background: Interleukin-32 (IL-32) is a proinflammatory cytokine, which acts as an important pathogenetic factor in various diseases and malignancies. However, the clinical significance of IL-32 expression in renal cell carcinoma has not been previously investigated. Methods: We examined 112 patients with localized clear cell renal cell carcinoma (CCRCC) who underwent nephrectomy. The clinicopathologic data were obtained by retrospective review and the expression levels of IL-32 were studied by immunohistochemistry. Tumors were classified into four scores based on the staining intensity (0, no staining intensity; 1, weak; 2, intermediate; 3, strong). The cases with staining intensities from 0 to 2 were included in the IL-32 low expression group (LEG); whereas, those with staining intensity of 3 were considered the IL-32 high expression group (HEG). Correlations between IL-32 expression and clinicopathologic features were determined. Results: Staining intensities were determined for all cases as follows: 26 cases (23.2%) (score 0), 43 cases (38.4%) (score 1), 31 cases (27.7%) (score 2), and 12 cases (10.7%) (score 3). IL-32 HEG showed a higher recurrence rate compared to the IL-32 LEG (50% vs. 13%, P=0.001). For survival rates, the 5-year recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) rates were lower in the IL-32 HEG compared with the IL-32 LEG (RFS, 87% vs. 50%, P = 0.001; DSS, 92% vs. 58.3%, P < 0.001; OS, 84% vs. 58.3%, P = 0.026, respectively). Univariate analyses showed that Fuhrman nuclear grade and high IL-32 expression were significant prognostic factors for predicting RFS, DSS, and OS in CCRCC; while, multivariate analyses indicated Fuhrman nuclear grade and high IL-32 expression (RFS, HR, 4.932, P = 0.009; DSS, HR 6.736, P = 0.002; OS, HR, 2.992, P = 0.037, respectively) were still independent risk factors. Conclusions: IL-32 overexpression was associated with high recurrence rates and low RFS, DSS, and OS, suggesting that it could be a novel prognostic factor for predicting outcomes in patients with CCRCC after a nephrectomy.

A phase II clinical trial examining the impact of neoadjuvant axitinib on primary tumor response in patients with locally advanced clear cell renal cell carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4516-4516 ◽  
Author(s):  
Jose A. Karam ◽  
Catherine E Devine ◽  
Marisa Lozano ◽  
Nizar M. Tannir ◽  
Kamran Ahrar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Clear Cell ◽  
Locally Advanced ◽  
Cell Renal Cell Carcinoma ◽  
Clear Cell Rcc ◽  
Tumor Downsizing

4516 Background: Previous studies have shown minimal impact of TKIs on primary renal tumor downsizing. Axitinib is a VEGFR TKI that has been recently approved for use in patients with metastatic clear cell renal cell carcinoma (RCC). In this prospective phase II trial, we sought to investigate the safety and role of axitinib in downsizing tumors in patients with non-metastatic renal cell carcinoma, prior to undergoing surgical resection. Methods: Patients with locally advanced (clinical stage T2-T3b N0 M0) biopsy-proven clear cell RCC were eligible for this phase II clinical trial. The primary outcome was objective response rate (using RECIST) following the administration of axitinib for 12 weeks prior to undergoing radical nephrectomy. Secondary outcomes included safety, tolerability, and feasibility of administration of axitinib in this patient population. Patients were given axitinib 5mg PO BID, and dose titration was allowed. Axitinib was continued until 36 hours prior to surgery. A dedicated radiologist independently reviewed all CT scans to evaluate for response using RECIST. Results: The study goal of enrolling 24 patients has been recently reached. At present, nineteen patients have completed the studies required for assessment of the primary outcome and are hereby reported. Fifteen patients were males, and four were females. Median age was 61 years (range 42-83 years). All patients had biopsy-proven clear cell RCC. All 19 patients continued axitinib for 12 weeks, and underwent surgery as planned without delay. Adverse events of any grade were: arthralgia in 6, hypothyroidism in 14, fatigue in 15, and hypertension in 16 patients. No wound complications occurred after surgery. Nine patients (47%) experienced a partial response by RECIST, and 10 patients had stable disease. There was no progression of disease while on axitinib. Conclusions: Axitinib is well tolerated in the neoadjuvant setting in patients with planned surgery for locally advanced non-metastatic clear cell RCC. The drug showed tumor downsizing activity when given for 12 weeks prior to surgery. Adverse events of any grade were common and easily manageable with routine care. Clinical trial information: NCT01263769.

Sign in / Sign up

Export Citation Format

Share Document